KR20210011961A - 단트롤렌 제제 및 그의 사용 방법 - Google Patents

단트롤렌 제제 및 그의 사용 방법 Download PDF

Info

Publication number
KR20210011961A
KR20210011961A KR1020207036289A KR20207036289A KR20210011961A KR 20210011961 A KR20210011961 A KR 20210011961A KR 1020207036289 A KR1020207036289 A KR 1020207036289A KR 20207036289 A KR20207036289 A KR 20207036289A KR 20210011961 A KR20210011961 A KR 20210011961A
Authority
KR
South Korea
Prior art keywords
dantrolene
pharmaceutical composition
administration
pharmaceutically acceptable
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207036289A
Other languages
English (en)
Korean (ko)
Inventor
찰스 웨스코트
질 코글란
Original Assignee
이글 파마슈티컬즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이글 파마슈티컬즈 인코포레이티드 filed Critical 이글 파마슈티컬즈 인코포레이티드
Publication of KR20210011961A publication Critical patent/KR20210011961A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207036289A 2018-05-21 2019-05-21 단트롤렌 제제 및 그의 사용 방법 Ceased KR20210011961A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862674394P 2018-05-21 2018-05-21
US62/674,394 2018-05-21
PCT/US2019/033260 WO2019226621A1 (en) 2018-05-21 2019-05-21 Dantrolene formulations and methods of their use

Publications (1)

Publication Number Publication Date
KR20210011961A true KR20210011961A (ko) 2021-02-02

Family

ID=66821419

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207036289A Ceased KR20210011961A (ko) 2018-05-21 2019-05-21 단트롤렌 제제 및 그의 사용 방법

Country Status (15)

Country Link
US (1) US20210236467A1 (https=)
EP (1) EP3796889A1 (https=)
JP (2) JP7762489B2 (https=)
KR (1) KR20210011961A (https=)
CN (1) CN112135605A (https=)
AU (1) AU2019272577B2 (https=)
BR (1) BR112020023012A2 (https=)
CA (1) CA3101093A1 (https=)
IL (1) IL278575B1 (https=)
MA (1) MA52707A (https=)
MX (2) MX2020012464A (https=)
SG (1) SG11202011121UA (https=)
UA (1) UA127661C2 (https=)
WO (1) WO2019226621A1 (https=)
ZA (1) ZA202006986B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419795A (zh) * 2020-05-09 2020-07-17 上药东英（江苏）药业有限公司 一种注射用丹曲林钠混悬剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1361092A (en) 1992-03-10 1993-10-05 Kyukyu Pharmaceutical Co., Ltd. Pharmaceutical preparation for percutaneous administration
JPH06263636A (ja) * 1993-03-12 1994-09-20 Kiyoshi Kataoka 脳または高次神経疾患治療剤
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
EP1603513B1 (en) * 2003-03-04 2020-12-30 Lyotropic Therapeutics, Inc. Dantrolene compositions
WO2010126818A1 (en) * 2009-04-27 2010-11-04 Usworldmeds Llc Intranasal delivery system for dantrolene
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions

Also Published As

Publication number Publication date
AU2019272577B2 (en) 2024-08-08
MA52707A (fr) 2021-03-31
JP2021524855A (ja) 2021-09-16
CN112135605A (zh) 2020-12-25
ZA202006986B (en) 2024-04-24
MX2025002392A (es) 2025-04-02
IL278575A (https=) 2021-01-31
IL278575B1 (en) 2026-03-01
UA127661C2 (uk) 2023-11-22
JP2024023270A (ja) 2024-02-21
CA3101093A1 (en) 2019-11-28
SG11202011121UA (en) 2020-12-30
AU2019272577A1 (en) 2020-11-26
BR112020023012A2 (pt) 2021-02-02
JP7762489B2 (ja) 2025-10-30
MX2020012464A (es) 2021-02-09
EP3796889A1 (en) 2021-03-31
WO2019226621A1 (en) 2019-11-28
US20210236467A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
ES2727854T3 (es) Formulaciones de péptidos que contienen propilenglicol que son óptimas para la producción y para su uso en dispositivos de inyección
ES2980828T3 (es) Pautas posológicas para el tratamiento de enfermedad de Pompe
KR20080030024A (ko) 도세탁셀의 약제학적 액상제제
US12186427B2 (en) Fulvestrant formulations and methods of their use
WO2018095848A1 (en) Pharmaceutical parenteral formulation containing carglumic acid
JP2024023270A (ja) ダントロレン製剤およびその使用方法
US9801859B2 (en) Bendamustine formulations
ES2363738T3 (es) Formulación de aviptadil.
US10052296B2 (en) Formulations for treating pain
RU2809143C2 (ru) Композиции дантролена и способы их применения
US20250018064A1 (en) Indocyanine compound-containing solid pharmaceutical composition
US20140107130A1 (en) Oral Solution Formulations of Aripiprazole
US20190070136A1 (en) Parenteral compositions of carmustine
US11590077B2 (en) Fulvestrant formulations and methods of their use
KR20220062367A (ko) p-보로노페닐알라닌을 함유하는 주사액제
US20240180935A1 (en) Solution formulation of cyclophosphamide
US20260108499A1 (en) Injectable formulations
US20250064758A1 (en) Antivirals targeting phosphatidic acid phosphatase (pap)
WO2025165852A1 (en) Liquid formulations of lurbinectedin
WO2022034545A1 (en) Etelcalcetide formulations for parenteral use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601